A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers
Information source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Canagliflozin/Probenecid (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Official(s) and/or principal investigator(s): Johnson & Johnson Pharmaceutical Research and Development, L.L.C Clinical Trial, Study Director, Affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Summary
The purpose of this study is to assess the effects of multiple doses of probenecid on the
multiple-dose pharmacokinetics of canagliflozin and its metabolites in healthy volunteers.
Safety and tolerability will also be assessed.
Clinical Details
Official title: An Open-Label, Fixed-Sequence Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Subjects
Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Plasma concentrations of Canagliflozin (including canagliflozin metabolites)Plasma concentrations of probenecid
Secondary outcome: Adverse EventsClinical Laboratory Tests Vital Signs
Detailed description:
This will be a single-center, open-label (identity of study treatments will be known to
volunteers participating in the study as well as to study staff) study to assess the effects
of multiple doses of probenecid on the multiple-dose pharmacokinetics of canagliflozin and
its metabolites in healthy volunteers. The study will last up to approximately 49 days
(includes a Screening Phase of up to 19 days, an Open-Label Treatment Phase of 20 days, and
a Post-Treatment Phase of up to 7 to 10 days). Healthy volunteers will take orally (by
mouth) one 300 mg canagliflozin tablet once daily and/or one 500-mg probenecid tablet twice
daily in sequential order as follows: Days 1 to 14 (administration of canagliflozin alone)
and Days 15 to 17 (administration of canagliflozin + twice-daily administration of
probenecid). On days when both canagliflozin and probenecid are taken, both doses must be
taken at approximately the same time.
Eligibility
Minimum age: 15 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria: Body mass index (BMI) between 18 and 28 kg/m² inclusive and a body
weight of not less than 50 kg. Exclusion Criteria: History of or current medical illness,
abnormal values for hematology or clinical chemistry laboratory tests, or abnormal
physical examination, vital signs or 12-lead electrocardiogram (ECG) deemed to be
clinically significant by the Investigator
Locations and Contacts
Overland Park, Kansas, United States
Additional Information
Starting date: August 2011
Last updated: February 16, 2012
|